Do analysts rate GUD or BHC?

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential upside of 0.21%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Knight Therapeutics is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, GUD or CRON?

Knight Therapeutics has higher revenue and earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Knight Therapeutics C$510.45M 1.82 -C$30.73M C$0.06 158.00 Cronos Group C$159.54M 8.81 -C$32.78M N/A N/A

Do analysts prefer THCX or GUD?

Knight Therapeutics has a consensus price target of C$9.50, indicating a potential upside of 0.21%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings & valuation, THCX or GUD?

Hydropothecary has higher earnings, but lower revenue than Knight Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hydropothecary N/A N/A N/A N/A N/A Knight Therapeutics C$510.45M 1.82 -C$30.73M C$0.06 158.00

Knight Therapeutics (GUD) Competitors

C$9.48 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

GUD vs. BHC, CRON, DHT.UN, THCX, and TLRY

Should you buy Knight Therapeutics stock or one of its competitors? MarketBeat compares Knight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Knight Therapeutics include Bausch Health Companies (BHC), Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), and Tilray Brands (TLRY). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Knight Therapeutics (TSE:GUD) and Bausch Health Companies (TSE:BHC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Knight Therapeutics has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.82	-C$30.73M	C$0.06	158.00
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Bausch Health Companies'average media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Bausch Health Companies	Neutral

Knight Therapeutics has a beta of -0.141784, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.942978, indicating that its stock price is 6% less volatile than the broader market.

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential upside of 0.21%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

23.9% of Knight Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Bausch Health Companies shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Knight Therapeutics has a net margin of 1.10% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Bausch Health Companies	-13.54%	120.43%	4.16%

Summary

Knight Therapeutics beats Bausch Health Companies on 10 of the 14 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Knight Therapeutics has a net margin of 1.10% compared to Cronos Group's net margin of -1.29%. Knight Therapeutics' return on equity of 0.73% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Cronos Group	-1.29%	-0.19%	-3.73%

Knight Therapeutics has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.82	-C$30.73M	C$0.06	158.00
Cronos Group	C$159.54M	8.81	-C$32.78M	N/A	N/A

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cronos Group	Neutral

Knight Therapeutics has a beta of -0.141784, meaning that its share price is 114% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.134248, meaning that its share price is 13% more volatile than the broader market.

23.9% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Cronos Group shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Knight Therapeutics currently has a consensus price target of C$9.50, suggesting a potential upside of 0.21%. Cronos Group has a consensus price target of C$4.75, suggesting a potential upside of 26.33%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Knight Therapeutics beats Cronos Group on 7 of the 12 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, DRI Healthcare Trust had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for DRI Healthcare Trust and 0 mentions for Knight Therapeutics. DRI Healthcare Trust's average media sentiment score of 1.16 beat Knight Therapeutics' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Overall Sentiment
DRI Healthcare Trust	Positive
Knight Therapeutics	Neutral

DRI Healthcare Trust presently has a consensus price target of C$25.50, indicating a potential upside of 37.47%. Knight Therapeutics has a consensus price target of C$9.50, indicating a potential upside of 0.21%. Given DRI Healthcare Trust's higher possible upside, equities analysts clearly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

DRI Healthcare Trust has a beta of 0.472401, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.141784, meaning that its stock price is 114% less volatile than the broader market.

0.6% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 23.9% of Knight Therapeutics shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DRI Healthcare Trust has higher earnings, but lower revenue than Knight Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$163.77M	6.23	C$9.73M	-C$0.90	N/A
Knight Therapeutics	C$510.45M	1.82	-C$30.73M	C$0.06	158.00

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of 1.10%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Knight Therapeutics	1.10%	0.73%	0.51%

Summary

DRI Healthcare Trust beats Knight Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Knight Therapeutics compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Hydropothecary has higher earnings, but lower revenue than Knight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Knight Therapeutics	C$510.45M	1.82	-C$30.73M	C$0.06	158.00

Knight Therapeutics has a net margin of 1.10% compared to Hydropothecary's net margin of 0.00%. Knight Therapeutics' return on equity of 0.73% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Knight Therapeutics	1.10%	0.73%	0.51%

Knight Therapeutics has a consensus price target of C$9.50, indicating a potential upside of 0.21%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Hydropothecary's average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Hydropothecary	Neutral
Knight Therapeutics	Neutral

23.9% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Knight Therapeutics beats Hydropothecary on 9 of the 9 factors compared between the two stocks.

How does Knight Therapeutics compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Tilray Brands had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.07 beat Knight Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Neutral
Knight Therapeutics	Neutral

Tilray Brands presently has a consensus price target of C$13.30, suggesting a potential upside of 91.09%. Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential upside of 0.21%. Given Tilray Brands' higher possible upside, equities research analysts plainly believe Tilray Brands is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

4.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 23.9% of Knight Therapeutics shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tilray Brands has a beta of 3.007995, meaning that its share price is 201% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.141784, meaning that its share price is 114% less volatile than the broader market.

Knight Therapeutics has a net margin of 1.10% compared to Tilray Brands' net margin of -158.75%. Knight Therapeutics' return on equity of 0.73% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-158.75%	-88.06%	-1.41%
Knight Therapeutics	1.10%	0.73%	0.51%

Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$858.28M	0.98	-C$183.24M	-C$14.63	N/A
Knight Therapeutics	C$510.45M	1.82	-C$30.73M	C$0.06	158.00

Summary

Knight Therapeutics beats Tilray Brands on 11 of the 16 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUD vs. The Competition

Export

Metric	Knight Therapeutics	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$930.74M	C$2.39B	C$6.52B	C$12.19B
Dividend Yield	N/A	2.94%	2.67%	6.19%
P/E Ratio	158.00	5.02	24.00	36.94
Price / Sales	1.82	1,639.28	516.42	10.45
Price / Cash	3.85	10.18	27.48	82.29
Price / Book	1.19	10.41	10.74	4.47
Net Income	-C$30.73M	C$20.27B	C$3.57B	C$299.09M
7 Day Performance	3.72%	-0.99%	0.58%	0.65%
1 Month Performance	12.46%	5.83%	1.48%	-0.08%
1 Year Performance	57.21%	15.90%	25.41%	41.90%

Knight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUD Knight Therapeutics	0.2835 of 5 stars	C$9.48 flat	C$9.50 +0.2%	+57.2%	C$930.74M	C$510.45M	158.00	725
BHC Bausch Health Companies	0.3615 of 5 stars	C$7.26 +1.1%	N/A	-12.7%	C$2.71B	C$10.53B	N/A	19,900
CRON Cronos Group	2.0585 of 5 stars	C$3.82 -0.5%	C$4.75 +24.3%	+43.0%	C$1.43B	C$159.54M	N/A	450	Gap Up
DHT.UN DRI Healthcare Trust	2.9651 of 5 stars	C$18.41 -1.9%	C$25.50 +38.5%	+39.2%	C$1.01B	C$163.77M	N/A	N/A	Positive News
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, CRON, DHT.UN, THCX, and TLRY

How does Knight Therapeutics compare to Bausch Health Companies?

Summary

How does Knight Therapeutics compare to Cronos Group?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Summary

How does Knight Therapeutics compare to Hydropothecary?

Summary

How does Knight Therapeutics compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, CRON, DHT.UN, THCX, and TLRY

How does Knight Therapeutics compare to Bausch Health Companies?

Which has preferable valuation and earnings, GUD or BHC?

Does the media favor GUD or BHC?

Which has more risk & volatility, GUD or BHC?

Do analysts rate GUD or BHC?

Do insiders and institutionals believe in GUD or BHC?

Is GUD or BHC more profitable?

Summary

How does Knight Therapeutics compare to Cronos Group?

Is GUD or CRON more profitable?

Which has better earnings & valuation, GUD or CRON?

Does the media prefer GUD or CRON?

Which has more volatility & risk, GUD or CRON?

Do insiders & institutionals have more ownership in GUD or CRON?

Do analysts rate GUD or CRON?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Does the media refer more to DHT.UN or GUD?

Do analysts prefer DHT.UN or GUD?

Which has more volatility and risk, DHT.UN or GUD?

Do insiders & institutionals believe in DHT.UN or GUD?

Which has better valuation and earnings, DHT.UN or GUD?

Is DHT.UN or GUD more profitable?

Summary

How does Knight Therapeutics compare to Hydropothecary?

Which has higher earnings & valuation, THCX or GUD?

Is THCX or GUD more profitable?

Do analysts prefer THCX or GUD?

Does the media refer more to THCX or GUD?

Do institutionals and insiders believe in THCX or GUD?

Summary

How does Knight Therapeutics compare to Tilray Brands?

Does the media refer more to TLRY or GUD?

Do analysts prefer TLRY or GUD?

Do insiders and institutionals hold more shares of TLRY or GUD?

Which has more volatility & risk, TLRY or GUD?

Is TLRY or GUD more profitable?

Which has higher valuation and earnings, TLRY or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools